NCT01627613View on ClinicalTrials.gov

Study in Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung Injury

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

August 31, 2014

Conditions
Acute Lung Injury
Interventions
DRUG

AP301

"AP301 25 mg powder for reconstitution for solution for inhalation~Orally delivered doses of 87.6 mg AP301 are inhaled every 12 hours (± 30 min), for a total of 7 days."

DRUG

Saline solution

Placebo solution (0.9% physiologic NaCl) is inhaled every 12 hours (± 30 min), for a total of 7 days.

Trial Locations (1)

1090

Department of Anesthesia, General Intensive Care and Pain Control,Medical University of Vienna, Vienna

All Listed Sponsors
lead

Apeptico Forschung und Entwicklung GmbH

INDUSTRY

NCT01627613 - Study in Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung Injury | Biotech Hunter | Biotech Hunter